HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent one of the most significant classes of drugs for the treatment of AIDS/HIV infection. Over the past two decades several potent arylsulfone-based HIV-1 NNRTIs and related analogs have been developed. This review provides an essential overview of the structure-activity relationships of the arylsulfone-based HIV-1 NNRTIs. Furthermore, structural information useful for the design and development of new sulfur containing NNRTIs with enhanced antiretroviral activity against HIV-1 wild type and clinically relevant drug resistant HIV-1 mutant strains will be discussed. © 2013 Future Science Ltd.
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors / Famiglini, V.; Coluccia, A.; Brancale, A.; Pelliccia, S.; La Regina, G.; Silvestri, R.. - In: FUTURE MEDICINAL CHEMISTRY. - ISSN 1756-8919. - 5:18(2013), pp. 2141-2156. [10.4155/fmc.13.174]
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors
Pelliccia S.;
2013
Abstract
HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent one of the most significant classes of drugs for the treatment of AIDS/HIV infection. Over the past two decades several potent arylsulfone-based HIV-1 NNRTIs and related analogs have been developed. This review provides an essential overview of the structure-activity relationships of the arylsulfone-based HIV-1 NNRTIs. Furthermore, structural information useful for the design and development of new sulfur containing NNRTIs with enhanced antiretroviral activity against HIV-1 wild type and clinically relevant drug resistant HIV-1 mutant strains will be discussed. © 2013 Future Science Ltd.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
